In vitro and

Sofia A Omari, Hansen J Kosasih, Thomas Chung, Charles E de Bock

Open access · goldAbstract read

In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact, top 73% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sofia A OmariChildren's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney 2052, Australia.

Hansen J KosasihChildren's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney 2052, Australia.

Thomas ChungChildren's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney 2052, Australia.

Charles E de BockChildren's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney 2052, Australia.

UNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mutations within the IL7-R-JAK-STAT signaling pathway are important drivers of T-cell acute lymphoblastic leukemia (T-ALL). Here we describe the important steps required to generate retroviral particles for the stable expression of mutant JAK3 constructs that induce constitutive JAK/STAT signaling. These are subsequently used for the viral transduction of the IL-3 cytokine-dependent Ba/F3 cell line or murine hematopoietic stem and progenitor cells (HSPCs) for

Indexed as

Bone marrow transplantCytokine-independent growthflow cytometryHematopoietic stem and progenitor cellsJAK3Mouse modelRetroviral transductionSTAT5T-cell acute lymphoblastic leukemiaTransfection

Identifiers

PMID38053908

DOI10.1016/j.heliyon.2023.e22085

PMCPMC10694137

OpenAlexW4388485679

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.